Optimising market access for biosimilarsWe speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for Share XOptimising market access for biosimilarshttps://pharmaphorum.com/views-analysis-market-access/optimising-market-access-for-biosimilars/
It’s good to talk, NICE says to pharma industry groupNICE has entered into a new dialogue with industry to highlight the benefits of its early scientific advice Share XIt’s good to talk, NICE says to pharma industry grouphttps://pharmaphorum.com/views-analysis-market-access/its-good-to-talk-nice-says-to-pharma-industry-group/
Nine for 2019: Opportunities for pharmaIn the last Nine for 2019 article, we reflected on the major challenges that are shaping the pharmaceutical Share XNine for 2019: Opportunities for pharmahttps://pharmaphorum.com/views-and-analysis/nine-for-2019-opportunities-for-pharma/
Nine for 2019: Challenges impacting pharmaAs we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping Share XNine for 2019: Challenges impacting pharmahttps://pharmaphorum.com/r-d/views-analysis-r-d/nine-for-2019-challenges-impacting-pharma/
Gene therapy and market access: the pharmaphorum podcastFor episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio Share XGene therapy and market access: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gene-therapy-market-access
US healthcare reform scenarios and their impact on the systemIn an effort to control healthcare costs, provide healthcare to the uninsured and underinsured, and improve health outcomes, Share XUS healthcare reform scenarios and their impact on the systemhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/icon-us-healthcare-reform-scenarios/
VPAS 2024: What should industry consider next time?The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share XVPAS 2024: What should industry consider next time?https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
China in the fast laneBrett Gardiner and Boon Yap from Research Partnership discuss access opportunities for novel therapies in the world’s hottest Share XChina in the fast lanehttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/research-partnership-pharma-market-access-china/
Market access round-up: the UK opens up to innovationWhen it comes to market access in the UK, the public’s eye has mostly been on the ongoing Share XMarket access round-up: the UK opens up to innovationhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-the-uk-opens-up-to-innovation/
